[Ibandronate as a new therapeutic agent for osteoporosis.]

Author(s): Goto H, Inaba M

Affiliation(s): Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.

Publication date & source: 2005-01, Clin Calcium., 15(1):15-7.

Publication type: English Abstract; Review

Ibandronate, a second generation amino-bisphosphonate has a high potency as much as the third generation bisphosphonates. Therefore this compound can be characteristically administrated by means of bolus intravenous injection. Moreover it is the first bisphosphonate prospectively shown antifracture efficacy for the intermittent administration in a randomized, controlled clinical trial.